Unique self-activating proteins for drug discovery
Explore cutting-edge hit-to-lead insights through exclusive interviews and studies by leading experts in the field.
List view / Grid view
Articles
Allosteric control sites in KRAS protein found
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
Unique self-activating proteins for drug discovery
Naegleria fowleri infections are rare but almost invariably fatal, with pathologic sequelae spawning its common label as ‘the brain-eating amoeba’. Researchers identified two unique proteins within N. fowleri – self-activating guanine nucleotide-hydrolysing proteins (G proteins) – that present novel targets for drug discovery. This article summarises their work to date,…
Advancing regenerative cell therapy development
In this interview we discuss with Alder Therapeutics regenerative cell therapy development through a proactive strategy, addressing manufacturing challenges early and ensuring a streamlined process. We explore an approach in pluripotent stem cell therapy development which eliminates complexities, minimises costs and expedites the delivery of transformative therapies.
The promise of nanobodies to neutralise the human norovirus
A new discovery about the dynamic structure of norovirus particles has implications for vaccine development.
Decoding stem cells for personalised regenerative medicine
Researchers developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging.
New biomarkers found for diabetic kidney disease
Biomarkers found through urinary and exosome proteome profiling have potential for diagnosis and disease monitoring.
Not all neoantigens are created equal
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
The potential of CD24 in cancer immunotherapy
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
Drug Target Review Proteomics eBook 2023
22 December 2023 | By
Download now! Drug Target Review breaks down the potential of stem cells for personalised regenerative medicine, offering practical insights into their role in healthcare.
Women in STEM with Dr Catherine Sheehan
In this special December edition of Women in STEM, we are privileged to feature Dr Catherine Sheehan, a distinguished figure whose journey in the field of STEM has been marked by passion, resilience, and impactful contributions. We explore her experiences, challenges faced, and the transformative impact of her work in…
Drug Target Review Immuno-oncology eBook 2023
22 December 2023 | By
Download this eBook for FREE. Explore cutting-edge immuno-oncology insights through exclusive interviews and studies by leading experts in the field.
Framework for understanding cell organisation and variation
From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organisation. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review.
Drug Target Review – Issue 4 2023
21 December 2023 | By
A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.
The future of mRNA biology and AI convergence
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly…
